Document is current
Any future updates will be listed below
-
Authors
He, Jing
Ao, Chunchun
Li, Mao
Deng, Taoran
Zheng, Shuo
Zhang, Ke
Tu, Chengshu
Ouyang, Yu
Lang, Ruibo
Jiang, Yijia
Yang, Yifan
Li, Changyong https://orcid.org/0000-0003-4001-037X
Wu, Dongcheng
-
Funding
Funding for this research was provided by:
Science and Technology Bureau, Guiyang Municipal Government (2023020402010771)
Innovation and Entrepreneurship Talent, GuangzhouProject of Lanzhou (202001002)
Key Research and Development Plan of Hubei Province (2021BCA134)
Key Research Project of Wuhan Donghu New Technology Development Zone (2022KJB118)
- License Information
-
More Information
Article History
Received: 30 April 2024
Accepted: 5 September 2024
First Online: 13 September 2024
Declarations
:
: The research project was conducted according to the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments). The animal studies were approved by the Committee of Animal Care and Use at Hubei Provincial Center for Food and Drug Safety Evaluation and Animal Experiment (Project title: The mechanism research of human umbilical cord mesenchymal stem cells and extracellular vesicles against chemotherapeutic drug-induced premature ovarian failure. The Permit Number: 202210022. Feb 23, 2022) and approved by the Bestcell Model Biological Center Notification of the Result for Ethical Approval for Research Involving Animals (Project title: Reach of pathological process of premature ovarian failure model induced by chemotherapy. The permit Number: BSMS 2022-06-27A. JUN 27, 2022). UC-MSCs were obtained following informed, written patient consent, and the approval was obtained by the Institutional Ethics Review Board of Renmin Hospital of Wuhan University (Project title: Clinical study of human umbilical cord mesenchymal stem cells for the treatment of diabetic nephropathy. The permit Number: WDRY2019-G001. Nov 22, 2019).
: Not applicable.
: The authors declare that there is no conflict of interest regarding the publication of this paper.
